Zoledronic acid/cisplatin-loaded cucurbit[7]uril-modified upconversion nanoformulations drive tumor-associated macrophage polarization and potentiate the efficacy of cancer immunotherapy
Restricted accessResearch articleFirst published online 2026
Zoledronic acid/cisplatin-loaded cucurbit[7]uril-modified upconversion nanoformulations drive tumor-associated macrophage polarization and potentiate the efficacy of cancer immunotherapy
Tumor-associated macrophages (TAMs) play a pivotal role in establishing a tumor immunosuppressive microenvironment (TIME) by inducing a phenotypic shift in macrophage from the pro-inflammatory M1 to the anti-inflammatory M2 phenotype. This polarization facilitates tumor growth, progression, metastasis, immune evasion, and chemoresistance. Consequently, reprogramming the TIME by repolarizing TAMs has emerged as a promising approach in cancer therapy. In this study, we synthesized core-shell structured nanoparticles (UCNPs@CB-Zol-Pt) utilizing host-guest interactions between NaYF4:Yb/Er (UCNPs) and cucurbit[7]uril (CB). These nanoparticles were designed to polarize M2-like macrophages into M1-like macrophages and release tumor-associated antigens (TAAs), thereby potentially inducing the release of immunogenic cell death (ICD). Furthermore, the M1-type macrophages could ingest, process, and present TAAs generated from platinum-based chemotherapy through MHC class II molecules. This process simultaneously enhances the infiltration of helper and effector T cells into the TIME, thereby potentiating the efficacy of checkpoint blockade immunotherapy.
WildCP. The global cancer burden: necessity is the mother of prevention. Nat Rev Cancer2019; 19: 123–124.
2.
YanSQLuoZCLiZL, et al.Improving cancer immunotherapy outcomes using biomaterials. Angew Chem Int Ed Engl2020; 132(40): 17484–17495.
3.
ZhaoZWZhengLYChenWQ, et al.Delivery strategies of cancer immunotherapy: recent advances and future perspectives. J Hematol Oncol2019; 12: 126.
4.
NgwaWIraborOCSchoenfeldJD, et al.Using immunotherapy to boost the abscopal effect. Nat Rev Cancer2018; 18: 313–322.
5.
RileyRSJuneCHLangerR, et al.Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov2019; 18: 175–196.
6.
Van der MeelRSulheimEShiY, et al.Smart cancer nanomedicine. Nat Nanotechnol2019; 14: 1007–1017.
7.
De HenauORauschMWinklerD, et al.Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature2016; 539: 443–447.
8.
TangTYHuangXZhangG, et al.Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Sig Transduct Target Ther2021; 6: 72.
9.
PathriaPLouisTLVarnerJA. Targeting tumor-associated macrophages in cancer. Trends Immunol2019; 40(4): 310–327.
10.
WanYFYuWJLiJM, et al.Multi-functional carboxymethyl chitin-based nanoparticles for modulation of tumor-associated macrophage polarity. Carbohydr Polym2021; 267: 118245.
11.
GartrellRDMarksDKHartTD, et al.Quantitative analysis of immune infiltrates in primary melanoma. Cancer Immunol Res2018; 6(4): 481–493.
12.
ZhangWJWangXHGaoST, et al.Tumor-associated macrophages correlate with phenomenon of epithelial-mesenchymal transition and contribute to poor prognosis in triple-negative breast cancer patients. J Surg Res2018; 222: 93–101.
13.
SørensenMDDahlrotRHBoldtHB, et al.Tumour-associated microglia/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumour subtype. Neuropathol Appl Neurobiol2018; 44(2): 185–206.
14.
WangHLiPFWangL, et al.High numbers of CD68+ tumor-associated macrophages correlate with poor prognosis in extranodal NK/Tcell lymphoma, nasal type. Ann Hematol2015; 94(9): 1535–1544.
15.
TiainenSTumeliusRRillaK, et al.High numbers of macrophages, especially M2-like (CD163-positive), correlate with hyaluronan accumulation and poor outcome in breast cancer. Histopathology2015; 66(6): 873–883.
16.
HuYHeMYZhuLF, et al.Tumor-associated macrophages correlate with the clinicopathological features and poor outcomes via inducing epithelial to mesenchymal transition in oral squamous cell carcinoma. J Exp Clin Cancer Res2016; 35: 12.
17.
PedersenMBDanielsenAVHamilton-DutoitSJ, et al.High intratumoral macrophage content is an adverse prognostic feature in Anaplastic large cell lymphoma. Histopathology2014; 65(4): 490–500.
18.
GenardGLucasSMichielsC. Reprogramming of tumor-associated macrophages with anticancer therapies: radiotherapy versus chemo- and immunotherapies. Front Immunol2017; 8: 828.
19.
WangYLinYXQiaoSL, et al.Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment. Biomaterials2017; 112: 153–163.
20.
ShahbaziMASedighiMBauleth-RamosT, et al.Targeted reinforcement of macrophage reprogramming toward M2 polarization by IL-4-loaded hyaluronic acid particles. ACS Omega2018; 3: 18444–18455.
21.
FusserMØverbyeAPandyaAD, et al.Cabazitaxel-loaded poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft. J Control Release2019; 293: 183–192.
22.
PanTZhouQMiaoK, et al.Suppressing Sart1 to modulate macrophage polarization by siRNA-loaded liposomes: a promising therapeutic strategy for pulmonary fibrosis. Theranostics2021; 11(3): 1192–1206.
23.
ChenJSuFYDasD, et al.Glycan targeted polymeric antibiotic prodrugs for alveolar macrophage infections. Biomaterials2019; 195: 38–50.
24.
de LázaroIMooneyDJ. Obstacles and opportunities in a forward vision for cancer nanomedicine. Nat Mater2021; 20: 1469–1479.
25.
LuYYunxiangGRyanP, et al.Development of Y-shaped peptide for constructing nanoparticle systems targeting tumor-associated macrophages in vitro and in vivo. Mater Res Express2014; 1: 25007.
26.
QinXJLiuJXuYH, et al.Mesoporous Bi-contained radiosensitizer loading with DOX to repolarize tumor associated macrophages and elicit immunogenic tumor cell death to inhibit tumor progression. ACS Appl Mater Interfaces2020; 12(28): 31225–31234.
27.
WeisslederRPittetMJ. Imaging in the era of molecular oncology. Nature2008; 452: 580–589.
28.
MiaoQXieCZhenX, et al.Molecular afterglow imaging with bright, biodegradable polymer nanoparticles. Nat Biotechnol2017; 35(11): 1102–1110.
29.
SunYLZhangWJWangBM, et al.A supramolecular self-assembly strategy for upconversion nanoparticle bioconjugation. Chem Commun2018; 54(31): 3851–3854.
30.
HuangZLiuYHChenY, et al.Improving the performance of upconversion nanoprobe-based lateral flow immunoassays by supramolecular self-assembly core/shell strategies. Sensor Actuat B-Chem2020; 318: 128233.
31.
BenyettouFFahsHElkharragR, et al.Selective growth inhibition of cancer cells with doxorubicin-loaded CB-modified iron-oxide nanoparticles. RSC Adv2017; 7: 23827–23834.
32.
LiuBLiCXXieZX, et al.808 nm photocontrolled UCL imaging guided chemo/photothermal synergistic therapy with single UCNPs-CuS@PAA nanocomposite. Dalton Trans2016; 45(33): 13061–13069.
33.
WheateNJBuckDPDayAI, et al.Cucurbitn.uril binding of platinum anticancer complexes. Dalton Trans2006; 3: 451–458.
34.
PlumbJAVenugopalBOunR, et al.Cucurbit[7] uril encapsulated cisplatin overcomes cisplatin resistance via a pharmacokinetic effect. Metallomics2012; 4(6): 561–567.
35.
BenyettouFAlhashimiMO’ConnorM, et al.Sequential delivery of doxorubicin and zoledronic acid to breast cancer cells by CB-modified oxide nanoparticles. Acs Appl Mater Interfaces2017; 9(46): 40006–40016.
36.
BernalIMukhopadhyayUVirovetsAV, et al.Previously unrecognised hydronium Di-Cation in the Crystal structure of a cucurbituril derivative. Chem Commun2005; 30: 3791–3792.
37.
BenyettouFLalatonneYSainte-CatherineO, et al.Superparamagnetic nanovector with anti-cancer properties: gamma Fe2O3@Zoledronate. Int J Pharm2009; 379(2): 324–327.
38.
KulkarniAChandrasekarVNatarajanSK, et al.A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer. Nat Biomed Eng2018; 2: 589–599.
39.
JainNVogelV. Spatial confinement downsizes the inflammatory response of macrophages. Nat Mater2018; 17: 1134–1144.
40.
DavisMJTsangTMQiuY, et al.Macrophage M1/M2 polarization dynamically adapts to changes in cytokine microenvironments in Cryptococcus neoformans infection. mBio2013; 4(3): e00264.
41.
ZhuWWXuRYDuJY, et al.Zoledronic acid promotes TLR-4-mediated M1 macrophage polarization in bisphosphonate-related osteonecrosis of the jaw. FASEB J2019; 33(4): 5208–5219.
42.
De NardoDGRuffellB. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol2019; 19: 369–382.
43.
QianQCaoXWangB, et al.TNF-α-TNFR signal pathway inhibits autophagy and promotes apoptosis of alveolar macrophages in coal worker's pneumoconiosis. J Cell Physiol2019; 234(5): 5953–5963.
44.
WangWMXuXSMiaoCM. Kupffer cell-derived TNF-α triggers the apoptosis of hepatic dtellate cells through TNF-R1/caspase 8 due to ER stress. BioMed Res Int2020; 2020: 8035671.
45.
SindrilaruAPetersTWieschalkaS, et al.An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J Clin Investig2011; 121(3): 985–9970.
46.
LaskarAEilertsenJLiW, et al.SPION primes THP1 derived M2 macrophages towards M1-like macrophages. Biochem Biophys Res Commun2013; 441(4): 737–742.
47.
NeefjesJJongsmaMLMPaulP, et al.Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol2011; 11(12): 823–836.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
